why choose us

First received: September 05, 2023

Clinical Trial: Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES

Brief Summary: This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Read more